Comparing with a median PFS of 8‐11 months in stage IV EGFR‐mutant NSCLC patients treated with EGFR‐TKI therapy alone,41, 42 our results suggested that SBRT had an important role on prolonging PFS of oligometastatic EGFR‐mutant NSCLC patients, although the sample size was small. This evidence concerns the gene EGFR and non-small cell lung carcinoma.